Statin for Neuroprotection in Spontaneous Intracerebral Hemorrhage

Inclusion Criteria: * Age of 18 years or older * A clinical diagnosis of supratentorial intracerebral hemorrhage is confirmed by brain CT scan * Hematoma volume ≤40ml * The first dose of statin can be given within 24h of intracerebral hemorrhage symptom onset (if the patient is randomized to statin group) * Written informed consent Exclusion Criteria: * Presence of intraventricular hemorrhage or subarachnoid hemorrhage * Planned surgical hematoma evacuation by open craniotomy prior to randomization (planned minimally invasive surgery is not a contraindication to enrollment) * Suspected secondary intracerebral hemorrhage related to trauma, tumor, ruptured aneurysm or arteriovenous malformation, hemorrhagic transformation of an ischemic infarct, Moyamoya disease, or venous sinus thrombosis * Unable to swallow a statin pill and have contraindication to position a nasogastric tube * Active liver disease or hepatic dysfunction, defined as aspartate aminotransferase (AST), or alanine aminotransferase (ALT) ≥2 × the upper limit of normal * Known pregnancy, or positive pregnancy test, or breastfeeding * Other diseases or abnormalities that the investigator believed might compromise the patient's safety during the study * Historical modified Rankin scale score ≥2 * Life expectancy of less than 7 days * Participation in another clinical study within 30 days prior to screening for the present study * Prior use of statins within 1 month before intracerebral hemorrhage